Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis | Zendy

Ng YeeYung | Zendy; Lee ShouDong | Zendy; Wu ShiaoChi | Zendy; Yang WuChang | Zendy; Chiang ShoouShan | Zendy; Huang TungPo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Antibodies to hepatitis C virus in uremic patients on continuous ambulatory peritoneal dialysis

Author(s) -

Ng YeeYung,

Lee ShouDong,

Wu ShiaoChi,

Yang WuChang,

Chiang ShoouShan,

Huang TungPo

Publication year - 1991

Publication title -

journal of medical virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.782

H-Index - 121

eISSN - 1096-9071

pISSN - 0146-6615

DOI - 10.1002/jmv.1890350411

Subject(s) - continuous ambulatory peritoneal dialysis , medicine , hepatitis c virus , hemodialysis , ambulatory , peritoneal dialysis , antibody , dialysis , gastroenterology , incidence (geometry) , hepatitis c , immunoassay , virus , immunology , physics , optics

The prevalence of antibody to hepatitis C virus (anti‐HCV) among 101 uremic patients receiving continuous ambulatory peritoneal dialysis (CAPD) was evaluated using a synthetic peptidebased HCV antibodies enzyme immunoassay. Thirty (29.7%) were found anti‐HCV positive. This is significantly higher than 500 unselected paid blood donors (4.2%, P < 0.0001). Among CAPD patients, anti‐HCV positivity was found more frequently in patients who had received frequent and longer duration of hemodialysis previously (40.4% vs. 20.4%, P < 0.05). These findings suggest that hemodialysis patients have a higher risk of HCV infection. At present, CAPD may be a suitable way to reduce the incidence of HCV infection in uremic patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research